Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tumor genetics predict survival in nasopharyngeal cancer?

NCT ID NCT07741110

Knowledge-focused Sponsor: Hellenic Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study looks back at tissue samples from patients with nasopharyngeal carcinoma who took part in an earlier treatment trial. Researchers are using advanced genetic testing and protein analysis to look for markers linked to how long patients survive. The goal is to better understand which biological factors may influence outcomes and potentially guide more personalized treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This analysis could identify genetic or protein markers that help predict which patients with nasopharyngeal carcinoma are more likely to survive, potentially guiding more personalized treatment decisions in the future.
What could go wrong
Because this is a retrospective analysis of a previous trial, the findings may not be definitive and could fail to identify reliable markers. The small sample size and use of stored tissue samples may also limit the accuracy and generalizability of the results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

141 people

The number who actually took part.

Started

Oct 2003

Finished

Feb 2008

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with locally advanced nasopharyngeal carcinoma

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * biopsy-proven, previously untreated WHO type I, II or III NPC; * age \> or equal to 15 years * stage IIB-IVB according to the American Joint Committee on Staging of Cancer classification (AJCC 2002); * measurable or evaluable disease * no other primary tumors * performance status (PS) of 0-2 according to the Eastern Cooperative Oncology Group scale (ECOG) * adequate bone marrow, hepatic, renal and pulmonary function * adequate nutritional status to tolerate protocol treatment and * adequate mental status to follow instructions, keep appointments and provide written informed consent. Exclusion Criteria: * Secondary malignancies * age\< 15 years * ECOG PS 3-4 * Renal, hepatic, hematologic or pulmonary insufficiency

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasopharyngeal carcinoma (NPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasopharyngeal carcinoma (NPC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.